Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda’s Cell Therapy Alofisel Approved in Japan
Takeda Pharmaceutical said on September 27 that it has obtained Japanese regulatory approval for its cell therapy Alofisel (darvadstrocel) for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease. Alofisel, also known as…
To read the full story
Related Article
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
- Takeda Rolls Out Crohn’s Disease Cell Therapy Alofisel in Japan
December 1, 2021
- Takeda’s GI Biz Poised for Growth with 3 Products Now in Its Lineup
November 29, 2021
- Takeda’s Cell Therapy Alofisel Gets 5.62 Million Yen Price Tag
November 17, 2021
- Drug Pricing Rules to Be Applied to Takeda’s Cell Therapy Alofisel: Chuikyo
October 14, 2021
- Takeda’s 1st Cell Therapy Up for PAFSC Review on Sept. 6
August 24, 2021
BUSINESS
- Eisai to Discontinue Tazverik in Japan over Secondary Cancer Risk
March 19, 2026
- BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
March 19, 2026
- Blenrep, Monjuvi, Zynyz, and More New Drugs Hit Japan Market
March 19, 2026
- Celltrion, CMIC Forge Broad Partnership in Japan Biosimilars Business
March 19, 2026
- J&J Launches Nurse-Led Support Program for Lung Cancer Patients in Japan
March 19, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…